1. COVID-19 in Neonates and Infants: Progression and Recovery.
- Author
-
Ng KF, Bandi S, Bird PW, and Wei-Tze Tang J
- Subjects
- Anti-Bacterial Agents therapeutic use, Betacoronavirus isolation & purification, Betacoronavirus pathogenicity, C-Reactive Protein metabolism, COVID-19, Coronavirus Infections blood, Disease Progression, Female, Fever virology, Humans, Infant, Infant, Newborn, Male, Neutropenia drug therapy, Neutropenia virology, Pandemics, Pneumonia, Viral blood, SARS-CoV-2, Sepsis drug therapy, Sepsis virology, Thrombocytosis drug therapy, Thrombocytosis virology, Coronavirus Infections physiopathology, Coronavirus Infections therapy, Pneumonia, Viral physiopathology, Pneumonia, Viral therapy
- Abstract
Between March 10, 2020 and April 17, 2020, of 8/70 (11.4%) SARS-CoV-2 positive infants that presented, 5/8 (63%) developed fever, 4/8 (50%) had lower respiratory tract involvement, 2/8 (25%) had neutropenia and thrombocytosis, and 4/8 infants (50%) were treated for suspected sepsis with broad-spectrum antibiotics. Only 1/8 (13%) required pediatric intensive care. All patients were eventually discharged home well.
- Published
- 2020
- Full Text
- View/download PDF